Ensysce Biosciences (ENSCW) Return on Capital Employed (2018 - 2025)
Ensysce Biosciences (ENSCW) reported Return on Capital Employed of 532.54% for Q3 2025, down 34068.0% year-over-year from N/an in Q3 2024, and down 106.63% quarter-over-quarter from 257.73% in Q2 2025.
Ensysce Biosciences (ENSCW) Return on Capital Employed (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 8 years of Return on Capital Employed data on file, last reported at 532.54% in Q3 2025.
- Return on Capital Employed for Q3 2025 came in at 532.54%, down 34068.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 532.54% (down 34068.0% YoY), and the FY2024 annual result was 345.94%, up 76636.0% from the prior year.
- Return on Capital Employed retreated to 532.54% in Q3 2025 per ENSCW's latest filing, from 257.73% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 2900.11% in Q4 2023 and troughed at 2378.87% in Q1 2023.
- A 5-year average of 185.07% and a median of 257.73% in 2025 frame the typical range for Return on Capital Employed.
- On a YoY basis, Return on Capital Employed climbed as much as 193542 bps in 2024 and fell as far as 302748 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 580.83% in 2021, then soared by 75 bps to 1019.12% in 2022, then jumped by 185 bps to 2900.11% in 2023, then slumped by 104 bps to 127.37% in 2024, then tumbled by 318 bps to 532.54% in 2025.
- Business Quant data shows ENSCW's Return on Capital Employed at 532.54% in Q3 2025, 257.73% in Q2 2025, and 205.02% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Ensysce Biosciences | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -532.54% |
| Jun 30, 2025 | -257.73% |
| Mar 31, 2025 | -205.02% |
| Dec 31, 2024 | -127.37% |
| Sep 30, 2024 | -191.87% |
| Jun 30, 2024 | -367.59% |
| Mar 31, 2024 | -443.45% |
| Dec 31, 2023 | 2,900.11% |
| Sep 30, 2023 | -499.10% |
| Jun 30, 2023 | -657.45% |
| Mar 31, 2023 | -2,378.87% |
| Dec 31, 2022 | 1,019.12% |
| Sep 30, 2022 | 528.37% |
| Jun 30, 2022 | -1,608.53% |
| Mar 31, 2022 | -431.09% |
| Dec 31, 2021 | 580.83% |
| Sep 30, 2021 | -779.92% |
| Jun 30, 2021 | -34.49% |
| Mar 31, 2021 | -29.67% |
| Dec 31, 2020 | 1,199.20% |